Advertisement
Home Dermatology PDF: Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature

PDF: Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature

$1.99

PDF Download: The addition of biologics that target IL-23p19 (Risankizumab) to our therapeutic armamentarium has succeeded in improving outcomes in patients with moderate-to-severe plaque psoriasis.

Category: